Abstract
Leukemia and lymphoma are hematologic neoplasms that affect members of all age groups. Each year, over 140,000 people in the US are diagnosed with a hematologic malignancy of some kind. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lymphomas and leukemias becomes more and more relevant to the survival of the patient, and immunohistochemistry has served as a key auxiliary test in determining these diagnoses. This presentation covers many of the basic science, facts, and statistics of hematologic malignancies, as well as the utility of immunohistochemical testing with markers such as CD20, PAX-5, CD61, CD71, Cyclin D1, and SOX-11 in the accurate diagnosis and survival rates of lymphoma and leukemia.
What Will You Learn?
- The advancements in immunohistochemical methods that enhance hematopathology
- The pathology of lymphoma and leukemia
- Innovative detection biomarkers including SOX-11, PAX-5, and CD71
- Demonstration of advanced staining on clinical samples
Who Should Attend?
- Histotechnologists
- Pathologists
- Oncologists
- Medical Directors
- Lab Managers
- Lab Technicians
- Residents/Histotech Students
- Health Care Professionals
Speakers
Jeff Gordon
Merck
OEM Sales Manager
Jeff Gordon is the OEM Sales Manager for Tissue Diagnostics. He has a Bachelor of Science in Microbiology from the University of Arkansas. In his over 17 years in the diagnostic Immunohistochemistry industry, he has served as a technical consultant managing territories covering most of the United States and Canada, as International Sales Manager, and as the Director of Sales and Marketing for Cell Marque before transitioning to OEM Sales Manager for us. His roles have involved sales, marketing, customer care/complaint handling, and product development. He has given over 60 IHC-related workshops and webinars at a local, state, national, and international level.
Protein biology
- Immunohistochemistry
期间:1h 3min
语言:English
场次 1:往期 April 27, 2018
如要继续阅读，请登录或创建帐户。
暂无帐户？